BioSpace News Archive

Omeros Corporation announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy (IgAN).

CanniMed announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc. (“Aurora”).

Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors.

Seattle Genetics, Inc. reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization for ADCETRIS (brentuximab vedotin) to include the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

The Telemark support microcatheter offers superior crossability for complex coronary and peripheral lesions.

Baxter announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).

As a consequence, Novartis will pay Genmab a lump sum of USD 50 million as payment for lost potential milestones and royalties.

The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.

The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board.

Hologic’s Cynosure division announced today the launch of TempSure Envi - an FDA-cleared advanced radiofrequency device that minimizes facial fine lines and wrinkles, tightens skin through soft tissue coagulation, and improves the appearance of cellulite.